- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01295619
Performance and Safety of I-020805 in Prevention of Cerebrospinal Fluid (CSF) Leakage Following Elective Craniotomy
A Prospective, Open, Multi-center, Single-arm Study of the Performance and Safety of I-020805 in the Prevention of Cerebrospinal Fluid Leakage Following Elective Cranial Surgery
Study Overview
Detailed Description
Patients who consented to participate in the trial and fulfilled the preoperative inclusion and exclusion criteria underwent screening prior to surgical treatment. After dural suturing, if patients met the intra operative inclusion and exclusion criteria, they received I-020805. If necessary, autologous grafts were to be used to augment dural closure.
I-020805 was delivered from a double syringe applicator that creates a fine layer over the dura. This layer quickly sets within seconds to form a watertight seal.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Pre-operative
- Male or female of 18 years old or over
- Elective cranial procedure entailing a dural incision of at least 2 cm in length
- Requires a procedure involving surgical wound classification Class I/Clean
- Signed informed consent form
- Negative pregnancy test at screening for women of childbearing potential and agreeing to use an acceptable birth control method or abstinence until 90 days post-surgery
Intra-operative
- Surgical wound classification Class I/Clean
- Dural margin from bony edges of at least 3 mm throughout
- Spontaneous expression of CSF assessed visually or a CSF leakage upon Valsalva maneuver
Exclusion Criteria:
Pre-operative
- Cranial procedure requiring translabyrinthine, transoral and/or any procedure penetrating the air sinus or mastoid air cells
- Presence of symptomatic hydrocephalus
- Pre-existing external ventricular drainage or lumbar CSF drain
- Radiotherapy in the planned surgical region which ended within 3 months prior to planned surgery
- Presence of systemic infection
- Known history of hemophilia or other clinically significant coagulopathy
- Known oral anticoagulant use
- Pregnancy or breast feeding
- Known allergy to any components of I-020805
- Previous participation in this trial or any investigational drug or device study within 30 day of screening
- Known clinically significant organ or systemic diseases
- Known or suspected non-compliance with trial procedures
Intra-operative
- Patient not meeting the pre-operative eligibility criteria
- Not able to tolerate a Valsalva maneuver
- Gap of more than 2 mm remaining after primary closure of dura
- Use of synthetic or non-autologous duraplasty material
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: I-020805
This was a prospective, open, multi-center, single-arm study to investigate I-020805 in patients following elective cranial surgery.
If they met the inclusion/ exclusion criteria, they receive I-020805 after suturing of the dura.
If necessary, autologous grafts were to be used to augment dural closure.
|
A thin layer of I-020805 applied up to two times on the sutured dura mater
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Performance of I-020805 in prevention of CSF leakage
Time Frame: Intraoperative on the day of sugery
|
Intraoperative on the day of sugery
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of CSF leakage
Time Frame: Within 7 days after surgery or prior to discharge
|
Within 7 days after surgery or prior to discharge
|
CSF leakage or pseudomeningocele related surgical intervention
Time Frame: Within 90 days following surgery
|
Within 90 days following surgery
|
CSF leakage confirmed by clinical evaluation or diagnostic testing
Time Frame: Within 90 days following surgery
|
Within 90 days following surgery
|
Surgical infection and unexpected neurological signs
Time Frame: Post-operative and within 7 days and 90 following surgery
|
Post-operative and within 7 days and 90 following surgery
|
Wound healing impairment
Time Frame: Throughout study up to 90 days following surgery
|
Throughout study up to 90 days following surgery
|
Incidence of all and treatment emergent adverse events
Time Frame: Throughout study up to 90 days following surgery
|
Throughout study up to 90 days following surgery
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CS I-020805/01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cerebrospinal Fluid Leakage
-
Integra LifeSciences CorporationMedtronic - MITGCompletedCerebrospinal Fluid Leakage, SubduralUnited States
-
University of ZurichCompletedCerebrospinal Fluid LeakageSwitzerland
-
University of GuadalajaraCompleted
-
Assiut UniversityRecruiting
-
Rawalpindi Medical CollegeRecruiting
-
Wuhan Union Hospital, ChinaNot yet recruiting
-
Universitaire Ziekenhuizen KU LeuvenRecruitingCerebrospinal FluidBelgium
-
Wake Forest University Health SciencesCompletedCerebrospinal Fluid ShuntsUnited States
-
Indiana University3-D Matrix Medical TechnologyNot yet recruitingSkull Base Neoplasms | Cerebrospinal Fluid Leakage | Nasal; Hypertrophy, Mucous Membrane (Septum)United States
Clinical Trials on I-020805
-
Hero Institute for Infant NutritionUniversidad de Murcia; University of Valencia; Universidad de GranadaCompletedConditions Influencing Health StatusSpain
-
VA Office of Research and DevelopmentActive, not recruitingInsomnia | Traumatic Brain InjuryUnited States
-
University of California, Los AngelesCompletedInsomnia ChronicUnited States
-
Helsinki University Central HospitalUniversity of Helsinki; Finnish Institute for Health and Welfare; Finnish Institute...RecruitingSchizophrenia | Schizoaffective Disorder | InsomniaFinland
-
Nottingham University Hospitals NHS TrustWellcome TrustCompleted
-
University of WuerzburgDeutsche Krebshilfe e.V., Bonn (Germany)RecruitingDifferentiated Thyroid CarcinomaGermany
-
Florida International UniversityAndrew Kukes Foundation for Social AnxietyCompleted
-
Chinese University of Hong KongNot yet recruitingAdolescent | Depression | InsomniaHong Kong
-
Haukeland University HospitalUppsala University; University of Bergen; University of AgderCompletedLymphoma | Breast Cancer | Colorectal Cancer | Prostate Cancer | Testicle CancerNorway
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...RecruitingFoot Diseases | Complex Regional Pain Syndromes | Pain, Joint | Ankle DiseaseItaly